Rein Therapeutics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-49.9M | $-62.9M | $-15.7M | $-27.3M | $-26.2M | $-27.3M | $-29.4M | $-31.5M |
| Depreciation & Amortization | $1.0K | $63.0K | $119.0K | $169.0K | $121.0K | $163.0K | $155.0K | $218.0K |
| Depreciation | — | — | $49.0K | $169.0K | $121.0K | $163.0K | $140.0K | $218.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $2.2M | $1.1M | $1.2M | $2.1M | $2.3M | $1.9M | $2.1M | $3.3M |
| Net Cash from Operating Activities | $-19.4M | $-22.3M | $-19.8M | $-24.9M | $-23.8M | $-20.5M | $-26.5M | $-27.9M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | $157.0K | $5.0K | $151.0K | $4.4M |
| Business Acquisitions | — | $0 | $96.0K | $0 | — | — | — | — |
| Net Cash from Investing Activities | — | $0 | $16.2M | $26.5M | $-35.9M | $6.4M | $-2.8M | $24.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $9.8M | $17.8M | $15.8M | — | $55.7M | $15.8M | $24.0M | $2.5M |
| Net Change in Cash | $-9.7M | $-4.5M | $12.1M | $1.6M | $-4.0M | $1.7M | $-5.3M | $-723.0K |
| Free Cash Flow | — | — | — | — | $-23.9M | $-20.5M | $-26.6M | $-32.3M |